27827
Pedro Marques da Silva, Carlos Aguiar
28. Ray KK, Cannon CP, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. Early and late
benefits of high- dose atorvastatin in patients with acute coronary syndromes: results from
the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46: 1405-10.
29. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Pre-
vention of cardiovascular events and death with pravastatin in patients with coronary heart
disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-57.
30. Kjekshus J, Pedersen T, Olsson A, et al. The effects of simvastatin on the incidence of heart
failure in patients with coronary heart disease. J Card Fail. 1997; 3: 249-54.
31. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of
Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease
(PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-30.
32. Scirica BM, Morrow DA, Cannon CP, et al. PROVE IT-TIMI 22 Investigators. Intensive statin
therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in
the PROVE IT-TIMI 22 Study. J Am Coll Cardiol. 2006; 47: 2326-31.
33. Kush KK, Waters DD, Bittner V, et al Effects of high-dose atorvastatin on hospitalizations
for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study. Circulation.
2007; 115: 576-83.
34. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after
myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent
Events Trial investigators. N Engl J Med. 1996; 335: 1001-9.
35. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with
systolic heart failure. N Engl J Med. 2007; 357: 2248-61.
36. Tavazzi L, Maggioni AP, Marchioli R, et al. Investigators. Effect of rosuvastatin in patients
with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-con-
trolled trial. Lancet. 2008; 372: 1231-9.
37. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid lowering with
simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359: 1343-56.
38. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Stroke Prevention by Aggressive Reduc-
tion in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or
transient ischemic attack. N Engl J Med. 2006; 355: 549-59.
39. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated
meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8: 453-63.
40. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovas-
cular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305.
41. Tonelli M, Keech A, Shepherd J, et al. . Effect of pravastatin in people with diabetes and
chronic kidney disease. J Am Soc Nephrol. 2005; 16: 3748-54.
42. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/
BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with
diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-16.
43. Wanner C, Krane V, März W, et al. German Diabetes and Dialysis Study Investigators.
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med.
2005; 353: 238-48.
